Dezső Tóth1, Zsolt Varga2, Judit Tóth3, Péter Árkosy3, Éva Sebő4. 1. Department of General Surgery, Kenézy Gyula University Hospital, University of Debrecen, 2-26 Bartók Street, Debrecen, 4031, Hungary. detoth@gmail.com. 2. Department of General Surgery, Kenézy Gyula University Hospital, University of Debrecen, 2-26 Bartók Street, Debrecen, 4031, Hungary. 3. Department of Oncology, Kenézy Gyula University Hospital, 2-26 Bartók Street, Debrecen, 4031, Hungary. 4. Department of Radiology, Breast Unit, Kenézy Gyula University Hospital, 2-26 Bartók Street, Debrecen, 4031, Hungary.
Abstract
BACKGROUND: A nationwide breast cancer screening program was introduced in Hungary in the year 2002 for women aged 45-65 years to be performed biannually. METHODS: To investigate and report the short-term and 10-year follow-up results, we analyzed our Breast Unit's prospectively led database of screened (Group A) and age-matched symptomatic (Group B) patients from 2002 to 2007. We compared the clinicopathologic features of tumors and the impact of screening on surgical treatment, as well as the overall (OS), disease-specific (DSS) and disease-free survival (DFS) of different groups. RESULTS: Data from 208 screen-detected and 101 symptomatic patients between 45 and 65 years of age were examined. Screen-detected women were younger (54 vs. 58.5 years; p = 0.001) had significantly smaller tumors (15.5 vs. 17 mm; p = 0.044), and more breast-conserving surgery (68.8 vs. 59.4%; p = 0.032). Survival statistics were not statistically different at the median follow-up of 123 months; however, there was a trend toward improved DFS in Group A (82.7 vs. 74.3%; p = 0.074). CONCLUSIONS: Our study showed a significant reduction in rates of mastectomy in the screen-detected group in the short term, which does not translate into better survival rates based on initial long-term data. In order to realize the real advantage of this newly enstated screening program, a longer period of investigation is needed.
BACKGROUND: A nationwide breast cancer screening program was introduced in Hungary in the year 2002 for women aged 45-65 years to be performed biannually. METHODS: To investigate and report the short-term and 10-year follow-up results, we analyzed our Breast Unit's prospectively led database of screened (Group A) and age-matched symptomatic (Group B) patients from 2002 to 2007. We compared the clinicopathologic features of tumors and the impact of screening on surgical treatment, as well as the overall (OS), disease-specific (DSS) and disease-free survival (DFS) of different groups. RESULTS: Data from 208 screen-detected and 101 symptomatic patients between 45 and 65 years of age were examined. Screen-detected women were younger (54 vs. 58.5 years; p = 0.001) had significantly smaller tumors (15.5 vs. 17 mm; p = 0.044), and more breast-conserving surgery (68.8 vs. 59.4%; p = 0.032). Survival statistics were not statistically different at the median follow-up of 123 months; however, there was a trend toward improved DFS in Group A (82.7 vs. 74.3%; p = 0.074). CONCLUSIONS: Our study showed a significant reduction in rates of mastectomy in the screen-detected group in the short term, which does not translate into better survival rates based on initial long-term data. In order to realize the real advantage of this newly enstated screening program, a longer period of investigation is needed.
Authors: Jeanne S Mandelblatt; Natasha K Stout; Clyde B Schechter; Jeroen J van den Broek; Diana L Miglioretti; Martin Krapcho; Amy Trentham-Dietz; Diego Munoz; Sandra J Lee; Donald A Berry; Nicolien T van Ravesteyn; Oguzhan Alagoz; Karla Kerlikowske; Anna N A Tosteson; Aimee M Near; Amanda Hoeffken; Yaojen Chang; Eveline A Heijnsdijk; Gary Chisholm; Xuelin Huang; Hui Huang; Mehmet Ali Ergun; Ronald Gangnon; Brian L Sprague; Sylvia Plevritis; Eric Feuer; Harry J de Koning; Kathleen A Cronin Journal: Ann Intern Med Date: 2016-01-12 Impact factor: 25.391
Authors: Gary M Freedman; Penny R Anderson; Lori J Goldstein; Alexandra L Hanlon; Mary E Cianfrocca; Michael M Millenson; Margaret von Mehren; Michael H Torosian; Marsha C Boraas; Nicos Nicolaou; Arthur S Patchefsky; Kathryn Evers Journal: Cancer Date: 2003-09-01 Impact factor: 6.860
Authors: Nathalie J Massat; Peter D Sasieni; Daniela Tataru; Dharmishta Parmar; Jack Cuzick; Stephen W Duffy Journal: Cancer Epidemiol Biomarkers Prev Date: 2015-12-08 Impact factor: 4.254
Authors: M Újhelyi; D Pukancsik; P Kelemen; E Kovács; I Kenessey; N Udvarhelyi; M Bak; T Kovács; Z Mátrai Journal: Eur J Surg Oncol Date: 2016-07-09 Impact factor: 4.424
Authors: Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray Journal: Int J Cancer Date: 2014-10-09 Impact factor: 7.396
Authors: Carme Miret; Laia Domingo; Javier Louro; Teresa Barata; Marisa Baré; Joana Ferrer; Maria Carmen Carmona-García; Xavier Castells; Maria Sala Journal: BMC Health Serv Res Date: 2019-12-05 Impact factor: 2.655